Uppsala -
The presentation will be made available on demand on the Bio Europe Digital website and accessible to attendees registered for the event. The presentation will also be uploaded onto Oasmia's website following the event.
Contact:
Tel: +46 18-50 54 40
Email: IR@oasmia.com
About
Oasmia is a specialty pharma company dedicated to improving the lives of patients by enhancing the intravenous delivery of established and novel drugs in significant diseases, including cancer. Product development is based on the Company's proprietary drug delivery technology platform XR-17 which can be applied to medicines used in many therapeutic areas, to develop water soluble formulations of drugs that currently require chemical solubilizers for dissolution. The first product approved using this technology is Apealea (paclitaxel micellar). Apealea has received market authorization in the
(C) 2020 Electronic News Publishing, source